Clinical trials: Coronavirus Disease-2019
Coronavirus Disease 2019 (COVID-19)
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.
- Trial name
- NCT04275245
- Testing
- Meplazumab for Injection
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Tang-Du Hospital
Coronavirus Disease 2019
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.
- Trial name
- NCT04678830
- Testing
- Leronlimab (700mg)
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- CytoDyn, Inc.
Covid19, SARS-CoV 2
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.
There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral…
- Conditions
- Covid19, SARS-CoV 2, Coronavirus Infection
- Trial name
- MeCOVID (NCT04353128)
- Testing
- Melatonin 2mg
- Where
- Spain
- Volunteers
- 450 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Infection Viral
Efficacy and Safety of Longan Extract Spray (P80 Spray) in Volunteers With Coronavirus Disease 2019 (COVID-19)
The objectives of this study are to evaluate efficacy and safety of longan extract spray (P80 spray) in volunteers with coronavirus disease 2019 (COVID19).Patients who infected COVID 19 (positive COVID 19 RT-PCR from nasal swab)…
- Trial name
- NCT04887233
- Testing
- Longan nasal spray
- Volunteers
- 60 people
- Sponsor
- Chulalongkorn University
Coronavirus Disease 2019
Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina
Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of…
- Trial name
- NCT04673279
- Testing
- serology
- Where
- Argentina
- Volunteers
- 189 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with…
- Trial name
- NCT05173441
- Testing
- Human COVID-19 immunoglobulin (pH4) for intravenous injection
- Where
- United Arab Emirates
- Volunteers
- 180 people
- Sponsor
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
COVID-19
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo.
- Trial name
- NCT04666441
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 57 sites in United States
- Volunteers
- 1,149 people
- Sponsor
- Regeneron Pharmaceuticals
COVID
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
- Trial name
- NCT04447469
- Testing
- mavrilimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 814 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc
Corona Virus Infection
Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
The aim of this effort is to study host-pathogen interaction in Egyptian patients infected with COVID-19. The investigators will perform genome-wide miRNA and transcriptome screens in the infected patients along with healthy ones…
- Trial name
- NCT04583566
- Testing
- COVID-19 Diagnostic and Assessment Tests
- Where
- 2 sites in Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tanta University
COVID-19 Infection
SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes
Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e.
- Trial name
- NCT04964024
- Testing
- SARS-CoV-2 antibodies
- Where
- France
- Volunteers
- 1,293 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
COVID-19, Cytokine Release Syndrome
Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;
Background: investigators have seen recently from experience in Western countries with best health care systems that pandemics cannot be managed in hospitals.
- Trial name
- Plex (NCT04485169)
- Testing
- Therapeutic Plasma Exchange
- Where
- Pakistan
- Volunteers
- 280 people
- Sponsor
- UNICEF
Covid19
Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity
NAPKON-HAP is the deep phenotyping platform of the National Pandemic Cohort Network (NAPKON) in Germany. NAPKON is a data and biospecimen collection of patients with COVID-19 and is part of the University Medicine Network (NUM)…
- Trial name
- NCT04747366
- Where
- 11 sites in Germany
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Coronavirus Infections
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and…
- Trial name
- COVID-19 (NCT04414618)
- Testing
- Opaganib
- Where
- 9 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- RedHill Biopharma Limited
COVID-19 Pneumonia
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might…
- Trial name
- NCT04901689
- Testing
- Leronlimab
- Where
- 23 sites in Brazil
- Volunteers
- 316 people
- Sponsor
- Hospital Israelita Albert Einstein
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Coronavirus Disease 2019, Vaccinia
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
comparison of general characteristics of patients diagnosed COVID-19 positive followed In service
- Conditions
- Coronavirus Disease 2019, Vaccinia, Symptoms and Signs
- Trial name
- COVID-19 (NCT05092568)
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Saglik Bilimleri Universitesi
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences
SARS-CoV Infection, COVID-19
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to…
- Conditions
- SARS-CoV Infection, COVID-19, Anosmia, Dysgeusia
- Trial name
- NCT04384042
- Testing
- Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
- Where
- 14 sites in Malaysia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Sultanah Bahiyah
Post ICU Syndrome, Chronic Pain
Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.
COVID-19 (coronavirus 2019) disease has led to a large number of hospital admissions, many of which require admission to intensive care (ICU).
- Conditions
- Post ICU Syndrome, Chronic Pain, Covid-19
- Trial name
- PAIN-COVID (NCT04394169)
- Testing
- Intervention program
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Hospital Clinic of Barcelona
Coronavirus Disease 2019 (COVID-19)
CSL324 in COVID-19
This is a phase 2, prospective, multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the safety and efficacy of intravenous (IV) administration of CSL324, administered in combination with…
- Trial name
- NCT04519424
- Testing
- CSL324
- Sponsor
- CSL Behring